Recently, lenvatinib, another multi-TKI with activity against VEGFR1-3, FGFR1-4, PDGF, RET, and KIT, has been approved as a first-line treatment in the management of advanced HCC patients and has demonstrated similar efficacy to sorafenib [5]. Here, FGFR1 is linked to hepatocellular carcinoma.